Compare EFOI & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | GRDX |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 28.6M |
| IPO Year | 2004 | N/A |
| Metric | EFOI | GRDX |
|---|---|---|
| Price | $3.68 | $5.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.2K | ★ 144.4K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.64 | $1.87 |
| 52 Week High | $9.84 | $5.40 |
| Indicator | EFOI | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 81.12 |
| Support Level | $3.49 | $2.08 |
| Resistance Level | $4.50 | N/A |
| Average True Range (ATR) | 0.32 | 0.56 |
| MACD | -0.07 | 0.16 |
| Stochastic Oscillator | 21.05 | 97.36 |
Energy Focus Inc specializes in designing, developing, manufacturing, and selling energy-efficient lighting systems and controls. It provides LED lighting solutions for both commercial and military maritime markets (MMM). Its core products include robust lighting fixtures and lamps for navy and military applications, Energy Storage Systems (ESS), Uninterruptible Power Supply (UPS), and tubular LED (TLED) lighting products, including battery backup units as well as general commercial and maritime lighting fixtures. The company operates in a single business segment that includes the marketing and sale of commercial and MMM lighting products and controls. The company generates a majority of its revenue from the sales of military maritime products in the United States.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.